Mithra reports full year 2023 financial results
Mithra reports full year 2023 financial results
Hyloris to Report 2023 Full-Year Results on 14 March 2024
Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET.
View post:
Hyloris to Report 2023 Full-Year Results on 14 March 2024
Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs – Yahoo News Canada
Scientists have created miniorgans from cells floating in the fluid that surrounds a fetus in the womb an advance they believe could open up new areas of prenatal medicine.
Miniorgans, or organoids, are tiny simplified structures that can be used to test new medical treatments or study how the real organs they mimic work, whether they are healthy or diseased.
Researchers from University College London and Great Ormond Street Hospital in the United Kingdom collected cells from amniotic fluid samples taken during 12 pregnancies as part of routine prenatal testing. Then, for the first time, they grew mini-organs from cells taken during active pregnancies. They envision their approach could eventually help doctors monitor and treat congenital conditions before birth and develop personalized therapies for a baby in the womb.
Were really excited about that possibility, said Mattia Gerli of University College London, an author of the study published Monday in the journal Nature Medicine.
The tissue-specific stem cells Gerli and his colleagues collected were shed by the fetus, as normally happens during pregnancy. The scientists identified which tissues the stem cells came from, and found cells from the lungs, kidneys and intestines.
Previously, mini-organs have been derived from adult stem cells, which more closely resemble adult tissue, or fetal tissue after an abortion.
Collecting cells from amniotic fluid gets around regulations about taking stem cells directly from fetal tissue, allowing these scientists to get cells from fetuses into the latter part of pregnancy. In the U.K., the legal limit for terminating a pregnancy is generally 22 weeks after conception. Scientists cant get fetal samples after that, limiting their ability to study normal human development or congenital diseases past that point.
In the U.S., abortion restrictions vary by state. Its legal in most to use fetal tissue for research, said Alta Charo, an emeritus professor of law and bioethics at the University of Wisconsin at Madison. Fetal tissue is defined by the National Institutes of Health as coming from a dead human embryo or fetus after a miscarriage, abortion or stillbirth and the use of tissue from an abortion has long been controversial.
Story continues
Charo, who wasn't involved in the study, said the new approach doesnt raise the same ethical issues. Obtaining cells from amniotic fluid that is already being sampled for standard clinical purposes does not appear to add any physical risks to either fetus or pregnant woman, she said in an email.
Dr. Arnold Kriegstein, who directs the Developmental and Stem Cell Biology Program at the University of California, San Francisco, and also wasn't involved in the research, said getting cells this way has the potential of giving you some information about that individual fetus as its growing.
And since growing mini-organs from cells in amniotic fluid takes about 4 to 6 weeks, Gerli said, there's enough time for prenatal therapy to fix problems doctors might find.
To examine one practical use of their approach, the U.K. team worked with colleagues in Belgium to study the development of babies with a condition called a congenital diaphragmatic hernia, in which organs such as the liver and intestines get displaced into the chest because of a hole in the diaphragm. The lungs dont develop the way they should, and about 30% of fetuses with the condition die. If doctors detect the hernia, they can operate on the fetus while it's still in the womb.
Researchers grew lung organoids from the cells of fetuses with the condition before and after treatment and compared them to organoids from healthy fetuses. Dr. Paolo de Coppi, an author of the study from University College London and Great Ormond Street Hospital, said they were able to assess the affected child's condition before birth using this method. Doctors are now unable to tell families much about the outcome of a prenatal diagnosis because each case is different, he said. The ability to study functioning prenatal miniorgans, he added, is the first step toward a more detailed prognosis and more effective treatments.
Kriegstein said more research is needed. Its in the very early stages," he added, "and well have to wait and see how useful itll be in the long run.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Science and Educational Media Group. The AP is solely responsible for all content.
Laura Ungar, The Associated Press
Originally posted here:
Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada
$343m investment to build stem-cell research center – BioProcess Insider – BioProcess Insider
Novo Nordisk Foundation will invest up to $343 million over a ten-year period to establish an international research center focused on stem cell medicine.
The center is a partnership entitled reNEW between the University of Copenhagen, Denmark, Murdoch Childrens Research Institute, Australia, and Leiden University Medical Center, The Netherlands.
The aim of the collaboration is to drive future stem cell-based treatments. The governing hub will be based at the Faculty of Health and Medical Sciences, University of Copenhagen and Melissa Little from the Murdoch Childrens Research Institute will serve as the CEO of the reNEW partnership, as well as being appointed executive director and professor of the center.
Image: Melissa Little, CEO of reNEW
reNEW builds international critical mass, expands the horizons and facilities available to all sites and enables the creation of international teams working towards targeted outcomes, Little told us.
She continued: Stem cell biology has come of age. The challenge now is to apply this understanding to outcomes that will benefit society whilst supporting these on research excellence.
Experts across the three institutions will work together to develop therapeutic options for patients with incurable diseases. According to the organization, the combination of exchange programs and joint technology platforms in the reNEW model will drive the partnership and train upcoming scientists in translational stem medicine.
My aim is to create an incentivized structure in which together the researchers can pivot to targeted product development and deliver these outcomes by creating more than the sum of the parts, Little said.
reNEW has separated the research into three themes, which includes the following:
reBUILD theme: This will focus on the use of stem cells to regenerate and/or recreate tissue once it has been damaged or destroyed. Programmes include stem cell-based therapies for diseases such as congenital heart disease, diabetes, ulcerative colitis and chronic renal disease, and Parkinsons disease.
reSOLVE theme: This sees the collaboration search for potential drug candidates using stem cell-based models of human tissue. This includes lab grown models of mini-organs to treat conditions like chronic ulceration and inherited kidney and heart disease.
reWRITE theme: This will use a combination of gene editing and stem cell technologies to produce treatment strategies for genetically inherited diseases. For example, immune deficiency disorders and progressive congenital muscle disorders.
My particular area of interest is kidney disease, said Little. While we are now able to recreate models of the human kidney from pluripotent stem cells, we wish to apply these to screen for treatments for inherited kidney disease and ultimately to bioengineer transplantable kidney tissue.
The $343 million funding will support 24 groups across the three sites together with advanced facilities available and accessible to researchers across the consortium.
Read more here:
$343m investment to build stem-cell research center - BioProcess Insider - BioProcess Insider
Cell Isolation/Cell Separation Market Growth, Development Factors, Business Insights, Value Chain and Sales … – Taiwan News
Introduction:
The global Cell Isolation/Cell Separation Market is on an unprecedented trajectory, projected to reach a staggering USD 17.3 billion by 2025, as reported by Report Ocean Market Research. This surge is underpinned by a myriad of factors, including the evolving landscape of medical research, the surge in stem cell isolation practices, and the increasing emphasis on personalized medicines. With North America currently dominating the market, closely followed by Europe and the Asia Pacific, the Cell Isolation/Cell Separation Market is witnessing a transformative phase with a focus on driving innovation for treating diseases like cancer.
Request To Download Free Sample of This Strategic Report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Market Dynamics:
For an in-depth analysis, you can refer sample copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Get a Free Sample PDF copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Key Market Players:
Leading the charge in the Cell Isolation/Cell Separation Market are prominent players like Thermo Fisher Scientific, BD Biosciences, Beckman Coulter, Merck & Company, GE Healthcare, STEMCELL Technologies Inc., Terumo BCT, Bio-Rad Laboratories Inc., PluriSelect Life Sciences, Sigma-Aldrich Corporation, Clontech Laboratories, and Miltenyi BioTec. These companies are at the forefront of technological advancements, relentlessly pursuing breakthroughs in personalized medicine and cell research.
Conclusion:
As the Cell Isolation/Cell Separation Market hurtles toward a projected valuation of USD 17.3 billion by 2025, it stands as a testament to the remarkable strides in medical research and treatment methodologies. The convergence of technological innovation, a surge in stem cell practices, and the global shift towards personalized medicine are reshaping the landscape of healthcare. The markets dynamics, driven by research and development, government funding, and a growing interest in stem cell isolation, underscore its transformative potential.
The dominance of consumables, the varied techniques employed, and the focus on human cell isolation collectively paint a comprehensive picture of a market on the cusp of revolutionary breakthroughs. As North America retains its stronghold and the Asia Pacific emerges as a powerhouse, the global community is poised to witness pioneering advancements in precision medicine and disease treatment. The market players, with their unwavering commitment to innovation, are steering the Cell Isolation/Cell Separation Market toward a future where tailored medical solutions redefine the boundaries of possibility.
These responses will function a complete examination of the:
Access Full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Report Ocean is a renowned provider of market research reports, offering high-quality insights to clients in various industries. Their goal is to assist clients in achieving their top line and bottom line objectives, thereby enhancing their market share in todays competitive environment. As a trusted source for innovative market research reports, Report Ocean serves as a comprehensive solution for individuals, organizations, and industries seeking valuable market intelligence.
Email:sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, United States
Telephone: +1 888 212 3539 (US Toll-Free)
For more information and to explore their offerings, visit their website at:https://www.reportocean.com/
See original here:
Cell Isolation/Cell Separation Market Growth, Development Factors, Business Insights, Value Chain and Sales ... - Taiwan News
Trends in Stem Cell Transplantation Refusal for Myeloma Treatment – Targeted Oncology
Determining the right path for multiple myeloma treatment is often complex as various decisions can significantly impact patient outcomes. Among these decisions, the consideration of autologous hematopoietic stem cell transplantation (HSCT) stands as a cornerstone, offering hope for improved progression-free and overall survival. However, recent research from Chakra Chaulagain, MD, showed that a small yet significant percentage of patients are refusing this potentially life-saving procedure.
An analysis of National Cancer Database (NCDB) data presented at the 2023 American Society of Hematology Annual Meeting showed that of 43,653 patients with newly diagnosed multiple myeloma recommended for HSCT, 98.05% proceeded with the procedure. However, the remaining 2% opted out. Some of the key factors influencing the patient's decision regarding HSCT related to socioeconomic, racial, and geographic disparities.
According to Chaulagain, director of the multiple myeloma and amyloidosis program at Cleveland Clinic Florida, older patients with multiple myeloma, those with comorbidities, and those lacking robust insurance coverage are more likely to decline HSCT. Furthermore, Black patients exhibited higher rates of refusal compared with White patients (OR, 1.38; P =.0022).
These findings underscore the need for future studies and policy changes to address socioeconomic and racial disparities in access to transplantation.
In an interview with Targeted OncologyTM, Chaulagain discussed the trends of rates of autologous HSCT refusal among patients with multiple myeloma.
Targeted Oncology: What led to your research on autologous HSCT refusal rates among patients with multiple myeloma?
Chaulagain: There is minimal data on real-world findings about refusal of a standard-of-care, for example, stem cell transplantation in [patients with] multiple myeloma. We wanted to explore some ideas about what are the factors that are contributing to the refusal transplant, which is the current standard-of-care, and it is known to improve both progression-free and overall survival based on randomized clinical trials. But there is limited real-world data around this subject, so we decided to investigate the NCDB.
Tumor microenvironment background with cancer cells, T-Cells, nanoparticles, molecules, and blood vessels. Oncology research concept: ratatosk - stock.adobe.com
What were the methods and design of this analysis?
This is a retrospective analysis of a very large number of [patients with] multiple myeloma that were treated by a commission of cancer-accredited cancer centers throughout the United States. There are at least 1500 of these types of cancer centers, and they report to this NCDB, where they have all of this data collected. NCDB captures about 70% of all cancer cases in the United States. We decided to get those data and analyze them just for multiple myeloma with the purpose of finding what are the variables and clinical factors that are responsible for refusal of autologous stem cell transplantation in [patients with] myeloma.
What were the key findings regarding the utilization of autologous HSCT in patients with multiple myeloma?
We had 43,600 patients [with] newly diagnosed multiple myeloma, and they were recommended to undergo a stem cell transplantation after completing their initial induction therapy by their doctors. Ninety-eight percent of the patients did go and do the stem cell transplantation, but 2% refused. We analyzed the various socioeconomic, racial, ethnic, and geographic factors about what made them refuse the stem cell transplantation.
Did the study identify any patient subgroups who were more likely to refuse?
We did find that older patients had a higher odds of refusing essential transplantation. Male [patients] had higher odds of accepting transplantation and females had higher odds of refusing it. Patients with more major medical comorbidities had higher odds of refusing it. Patients without insurance, or Medicare and Medicaid, had higher odds of refusing stem cell transplantation compared with patients who had private insurance. Median household income was also a significant predictor of whether the patient will go for a stem cell transplant or not. Those who were earning less than $63,000 annually had a higher odds of refusing autologous stem cell transplantation. Black patients, for example, had a higher odds of refusing transplantation, and Hispanic [patients] had a lower odds of refusing transplantation.
Were there any significant trends in the refusal rates over this time period?
The study time point was from 2004 until 2020. Patients who were diagnosed and treated closer to 2020 had a higher odds of refusing transplantation, and patients who were diagnosed closer to 2004 had a higher odds of accepting transplantation or lower odds of refusing transplantation, and we think it may have to do with advancement in novel therapies, particularly monoclonal antibody therapies in multiple myeloma in the current years.
What are the potential reasons as to why patients refused more than others?
The higher age, decreased income, not having strong private insurance, and also, the facility type did matter. For example, patients who were treated at nonacademic facilities had a higher odds of refusing transplant compared with patients that were treated at academic centers. There was also regional variation on whether the patient would refuse or accept transplant. For example, in South Atlantic states in the United States, patients had higher odds of refusing transplantation.
What are the implications of these findings?
We found that there was significant variation across the United States in terms of racial, economic, and geographic variation, and this data can and should be used for designing future clinical studies in a prospective basis.
How have recent advancements in the multiple myeloma space such as the emergence of novel therapies impacted transplantation?
Based on our studies, the emergence of novel therapies and immunotherapy, particularly anti-CD38 monoclonal antibodies like daratumumab [Darzalex], have led to decrease utilization of transplant, and it will probably further evolve down the road because of the availability of even more effective novel therapies such as [chimeric antigen receptor] T-cell therapy, and bispecific T-cell engager therapy. The role of transplant will continue to evolve and will probably continue to diminish down the road.
What barriers still need to be addressed regarding transplant?
These are bigger decisions at the policy and procedure and legislation [levels], like increasing incidence coverage, increasing socioeconomic aspects for all of our patients, particularly those who are marginalized or who are minorities. This is a bigger, national goal and the legislator has to act on it,
Read more from the original source:
Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology
Cell therapy for retinal degenerative disorders: a systematic review and three-level meta-analysis – Journal of … – Journal of Translational…
Thapa R, Khanal S, Tan HS, Thapa SS, van Rens G. Prevalence, pattern and risk factors of retinal diseases among an elderly population in Nepal: the Bhaktapur retina study. Clin Ophthalmol. 2020;14:210918.
PubMed PubMed Central Google Scholar
Chen TC, Huang DS, Lin CW, Yang CH, Yang CM, Wang VY, et al. Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan. NPJ Genom Med. 2021;6(1):16.
Article CAS PubMed PubMed Central Google Scholar
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):14757.
Article CAS PubMed Google Scholar
Tang Z, Zhang Y, Wang Y, Zhang D, Shen B, Luo M, et al. Progress of stem/progenitor cell-based therapy for retinal degeneration. J Transl Med. 2017;15(1):99.
Article PubMed PubMed Central Google Scholar
Molday RS, Zhang K. Defective lipid transport and biosynthesis in recessive and dominant Stargardt macular degeneration. Prog Lipid Res. 2010;49(4):47692.
Article CAS PubMed PubMed Central Google Scholar
Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.
Article PubMed PubMed Central Google Scholar
Mody S, Joshi A. Age-related macular degeneration and its association with neurodegenerative disorders. Cureus. 2023;15(2): e34920.
PubMed PubMed Central Google Scholar
Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021;105(3):47391.
Article PubMed Google Scholar
Liu W, Liu S, Li P, Yao K. Retinitis pigmentosa: progress in molecular pathology and biotherapeutical strategies. Int J Mol Sci. 2022;23(9):4883.
Article CAS PubMed PubMed Central Google Scholar
Wu X, Yan N, Zhang M. Retinal degeneration: molecular mechanisms and therapeutic strategies. Curr Med Chem. 2022;29(40):612540.
Article CAS PubMed Google Scholar
Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular dystrophy. Ophthalmic Genet. 2009;30(2):638.
Article PubMed Google Scholar
Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology. 2003;110(6):11518.
Article PubMed Google Scholar
Sharma A, Jaganathan BG. Stem cell therapy for retinal degeneration: the evidence to date. Biologics. 2021;15:299306.
PubMed PubMed Central Google Scholar
ner A. Stem cell treatment in retinal diseases: recent developments. Turk J Ophthalmol. 2018;48(1):338.
Article MathSciNet PubMed PubMed Central Google Scholar
Huang X, Gao H, Xu H. Editorial: stem cell-based therapy in retinal degeneration. Front Neurosci. 2022. https://doi.org/10.3389/fnins.2022.879659.
Article PubMed PubMed Central Google Scholar
Hinkle JW, Mahmoudzadeh R, Kuriyan AE. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer cell therapy clinics. Stem Cell Res Ther. 2021;12(1):538.
Article CAS PubMed PubMed Central Google Scholar
Soltani Khaboushan A, Shakibaei M, Kajbafzadeh A-M, Majidi ZM. Prenatal neural tube anomalies: a decade of intrauterine stem cell transplantation using advanced tissue engineering methods. Stem Cell Rev Rep. 2022;18(2):75267.
Article PubMed Google Scholar
Barker TH, Stone JC, Sears K, Klugar M, Leonardi-Bee J, Tufanaru C, et al. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth. 2023;21(3):494.
Article PubMed Google Scholar
Shi J, Luo D, Weng H, Zeng X-T, Lin L, Chu H, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):64154.
Article PubMed Google Scholar
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.
Article PubMed PubMed Central Google Scholar
Heeren TFC. The eye package for R: a tool to facilitate analysis of ophthalmic data. 2021.
Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):103846.
Article CAS PubMed Google Scholar
Arcieri R, Messias K, Castro V, Siqueira R, Jorge R, Messias A. Intravitreal autologous bone-marrow stem cells in retinitis pigmentosa patients: one-year results. Investig Ophthalmol Vis Sci. 2013;54(15):643.
Google Scholar
Arturo J, Perez C, Segura O, Guerrero OS, Bastidas Y, Larios L. Endovascular retinal infusion of bone marrow hematopoietic stem cells for pigmentous retinitis. Cytotherapy. 2014;16:S64.
Article Google Scholar
Banin E, Barak A, Boyer DS, Do DV, Ehrlich R, Jaouni T, et al. Phase I/IIa clinical trial of human embryonic stem Cell (hESC)-derived retinal pigmented epithelium (RPE, OpRegen) transplantation in advanced dry form age-related macular degeneration (AMD): interim results. Investig Ophthalmol Vis Sci. 2019;60(9):6402.
Google Scholar
Beliakouski P, Pozniak N, Kovchel N. The influence of mesechymal stem cells in macular degeneration. Acta Ophthalmol. 2012;90:4.
Google Scholar
Bharti K. Autologous iPSC-derived RPE transplantation for dry AMD. Investig Ophthalmol Vis Sci. 2018;59(9):3906.
Google Scholar
Coffey P. Human embryonic stem cell derived retinal pigment epithelium transplantation in severe exudative age-related macular degeneration: So far so visual. Investig Ophthalmol Vis Sci. 2017;58(8):4770.
Google Scholar
Cotrim CC, Jorge R, Messias A, De Sousa MV, Toscano L, Siqueira RC. Intravitreal autologous bone-marrow stem cells in nonexudative macular degeneration (dry AMD) patients: results after 3 months follow-up. Invest Ophthalmol Vis Sci. 2015;56(7):3783.
Google Scholar
Cotrim CC, Messias AMV, Jorge R, Siqueira RC. Intravitreal use of a bone marrow mononuclear fraction (BMMF) containing cd34+cells in patients with Stargardt type macular dystrophy. Stem Cells Int. 2020. https://doi.org/10.1155/2020/8828256.
Article PubMed PubMed Central Google Scholar
Cotrim CC, Toscano L, Messias A, Jorge R, Siqueira RC. Intravitreal use of bone marrow mononuclear fraction containing CD34+ stem cells in patients with atrophic age-related macular degeneration. Clin Ophthalmol. 2017;11:9318.
Article PubMed PubMed Central Google Scholar
da Cruz L, Fynes K, Georgiadis O, Kerby J, Luo YH, Ahmado A, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018;36(4):32837.
Article PubMed Google Scholar
DaCruz L, Fynes K, Georgiadis O, Nommiste B, Carr AJF, Ramsden C, et al. Improvement and stabilization of vision for 18 months after Human Embryonic Stem-cell (hESC) derived, RPE-sheet transplantation on a synthetic basement membrane for trestment of severe, wet age-related macular degeneration. Investig Ophthalmol Visual Sci. 2018;59(9):2985.
Google Scholar
De Sousa MV, Jorge R, Messias A, Cotrim CC, Rodrigues MW, Siqueira RC. Intravitreal autologous bone marrow derived stem cells in ischemic macular edema-results after 6 months follow-up. Invest Ophthalmol Vis Sci. 2015;56(7):4718.
Google Scholar
Francis PJ, Birch DG, Davis JL, Lam BL, Spencer R, Stout JT, et al. A phase 1 open-label, non-comparative study evaluating the safety of a single, unilateral subretinal administration of CNTO2476 (human umbilical tissue-derived cells hUTC ) in advanced retinitis pigmentosa (RP). Investig Ophthalmol Vis Sci. 2010;51(13):4789.
Google Scholar
Garca Inesta N, Iniesta F, Garca AV, Marn JM, Garca C, Rodrguez M, et al. Intravitreal injection of autologous bone marrow stem cells in retinitis pigmentosa patients. preliminary results of a phase I clinical trial. Bone Marrow Transplant. 2016;51:S3178.
Google Scholar
Georgiadis O, Fynes K, Luo Y, Nommiste B, Zhong J, Ramsden C, et al. Human embryonic stem Cell-derived retinal pigment epithelium sheet transplantation in severe neovascular age-related macular degeneration: 18-month survival and structural outcomes. Investig Ophthalmol Vis Sci. 2018;59(9):2984.
Google Scholar
Heier JS, Ho AC, Samuel MA, Chang T, Riemann CD, Kitchens JW, et al. Safety and efficacy of subretinally administered palucorcel for geographic atrophy of age-related macular degeneration phase 2b study. Ophthalmol Retina. 2020;4(4):38493.
Article PubMed Google Scholar
Ho AC, Chang TS, Samuel M, Williamson P, Willenbucher RF, Malone T. Experience with a subretinal cell-based gossmark therapy in patients with geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol. 2017;179:6780.
Article PubMed Google Scholar
Jain V, Kadam S. Bestrophinopathies: fighting blindness with stem cells. Cytotherapy. 2018;20(5):S42.
Article Google Scholar
Kahraman NS, Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial. Int J Ophthalmol. 2020;13(9):14239.
Article PubMed PubMed Central Google Scholar
Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Chen S, et al. One-year follow-up in a phase 1/2a clinical trial of an allogeneic rpe cell bioengineered implant for advanced dry age-related macular degeneration. Transl Vis Sci Technol. 2021;10(10):13.
Article PubMed PubMed Central Google Scholar
Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med. 2018;10(435):eaao4097.
Article PubMed Google Scholar
Kashani AH, Uang J, Mert M, Rahhal F, Chan C, Avery RL, et al. Surgical method for implantation of a biosynthetic retinal pigment epithelium monolayer for geographic atrophy: experience from a phase 1/2a study. Ophthalmol Retina. 2020;4(3):26473.
Article PubMed Google Scholar
Kumar A, Midha N, Mohanty S, Chohan A, Seth T, Gogia V, et al. Evaluating role of bone marrow-derived stem cells in dry age-related macular degeneration using multifocal electroretinogram and fundus autofluorescence imaging. Int J Ophthalmol. 2017;10(10):15528.
PubMed PubMed Central Google Scholar
Kuppermann BD, Boyer DS, Mills B, Yang J, Klassen HJ. Safety and activity of a single, intravitreal injection of human retinal progenitor cells (jCell) for treatment of retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2018;59(9):2987.
Google Scholar
Kwon NJ, Song W, Choi J, Chung SY, Kim HJ, Lee JH. The embryonic stem cell derived retinal pigment epithelial cell trial for Stargardt macular dystrophy: preliminary phase 1 results in Asian. Acta Ophthalmol. 2014. https://doi.org/10.1111/j.1755-3768.2014.F017.
Article Google Scholar
Li SY, Liu Y, Wang L, Wang F, Zhao TT, Li QY, et al. A phase I clinical trial of human embryonic stem cell-derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years follow-up. Cell Prolif. 2021. https://doi.org/10.1111/cpr.13100.
Article PubMed PubMed Central Google Scholar
Liao D, Boyer DS, Kaiser P, Kuppermann BD, Heier J, Mehta M, et al. Intravitreal injection of allogeneic human retinal progenitor cells (hRPC) for treatment of retinitis pigmentosa: a prospective randomized controlled phase 2b trial. Investig Ophthalmol Vis Sci. 2021;62(8):3240.
Google Scholar
Limoli PG, Limoli C, Vingolo EM, Scalinci SZ, Nebbioso M. Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget. 2016;7(30):4691323.
Article PubMed PubMed Central Google Scholar
Limoli PG, Limoli CSS, Morales MU, Vingolo EM. Mesenchymal stem cell surgery, rescue and regeneration in retinitis pigmentosa: Clinical and rehabilitative prognostic aspects. Restor Neurol Neurosci. 2020;38(3):22337.
See the rest here:
Cell therapy for retinal degenerative disorders: a systematic review and three-level meta-analysis - Journal of ... - Journal of Translational...
Japanese hospital to evaluate technology used in European trials – Labmate Online
Leading stem cell researchers at Shonan Kamakura General Hospital (SKGH), Japan, are collaborating with regenerative cell therapy developer CellProthera to manufacture autologous endothelial progenitor cells (EPCs) for use in forthcoming clinical trials. Led by world-renowned stem cell expert Takayuki Asahara, MD, PhD, the SKGH research team will use the companys automated manufacturing technology, along with single-use cell culture kits to produce therapies for patients with ischemic and renal diseases.
Professor Asahara, Deputy Director of Shonan Research Institute of Innovative Medicine atSKGH, was the first researcher to isolate EPCs from peripheral blood. EPCs are naturally deployed in the body to repair blood flow after it is restricted (as in ischemic stroke).
CellProtheras StemXpand, which has been in use in European trials to grow patients own cells into a therapeutic dose, will be rigorously tested to meet SKGHs manufacturing specifications and adapted as needed to begin qualification runs for an upcoming clinical trial. After the collaborators confirm consistency and reproducibility both in the manufacturing process and with the previously manufactured product, Prof. Asaharas team will perform validation runs to ready the technologys use for clinical testing.
We are honoured to work with Prof. Asahara given his ground-breaking experience in the regenerative medicine space and think he is the ideal partner to demonstrate the utility of our manufacturing technology beyond our own pipeline, said Matthieu de Kalbermatten, CEO, CellProthera. As a long-time advocate for the use of stem cells for the treatment of ischemic and renal diseases, I am hopeful this collaboration will pave the way for the StemXpand and StemPack to play a pivotal role in the research and development of stem cell treatments across the globe.
Ischemic diseases remain one of the leading causes of death in Japan, with limited treatment options, commented Prof. Asahara. We hand-picked CellProthera for collaboration based in part on how StemXpand, a tried and trusted technology, will help us meet the needs of patients with ischemic diseases through our development of targeted stem cell therapies.
More information online
Go here to see the original:
Japanese hospital to evaluate technology used in European trials - Labmate Online
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023.
Here is the original post:
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC
Read more here:
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results